Evaxion Biotech A/S — Form 6-K Summary
Business context and reporting period
Evaxion Biotech A/S filed a Form 6-K for the month of January 2024. The filing was submitted on January 10, 2024, by the company’s CEO, Christian Kanstrup. The company is a Danish foreign private issuer that files annual reports on Form 20-F.
Financial metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial performance metrics.
Material changes versus the prior comparable period
The filing does not report operating or financial changes versus a prior period.
Guidance, outlook, risks, contingencies, and unusual items
The principal matter disclosed is a convening notice for an Extraordinary General Meeting scheduled for January 11, 2024, at 3:00 p.m. Central European Summer Time. The notice was furnished as Exhibit 99.1; its substantive proposals are not included in the provided filing text.
The filing states that it is incorporated by reference into the company’s registration statements on Forms S-8, F-3, and F-1, to the extent not superseded by later filings.
Important facts to verify
- Review Exhibit 99.1 for the agenda, resolutions, voting requirements, and meeting materials for the Extraordinary General Meeting.
- Confirm any subsequent filings describing the outcome of the January 11, 2024 meeting.
- Consult the company’s Form 20-F and other periodic reports for financial performance, liquidity, financing needs, and risk disclosures, which are not presented in this Form 6-K.